

**Supplemental Table 1: Demographic and clinical features of PwMS**

Cohort	Race	Gender	MS Type	N	Age Onset	Age Diagnosis
VALOMS	AA	Male	RR	13	34.1 ± 3.0	37.7 ± 2.4
			SP	7	31.9 ± 4.0	35.6 ± 4.4 <b>a</b>
			Both	20	34.0 ± 2.3	37.0 ± 2.1
		Female	RR	8	28.1 ± 2.1	32.6 ± 2.6
			SP	5	32.4 ± 5.3	38.6 ± 5.6
			Both	13	29.8 ± 2.3	34.9 ± 2.7
		Both	RR	21	31.8 ± 2.1	35.8 ± 1.8
			SP	12	32.1 ± 3.0	36.8 ± 3.3 <b>a</b>
			Both	33	32.3 ± 1.7	36.2 ± 1.7 <b>a</b>
	White	Male	RR	24	34.0 ± 2.4	39.3 ± 2.3
			SP	20	39.2 ± 2.3 <b>h</b>	44.2 ± 1.9
			Both	44 *	36.4 ± 1.7	41.5 ± 1.6
		Female	RR	6	31.0 ± 4.1	36.5 ± 3.1
			SP	7	30.2 ± 4.0	44.0 ± 3.1
			Both	13	30.6 ± 2.7	40.5 ± 2.4
Both		RR	30	33.4 ± 2.1	38.7 ± 2.0 <b>d</b>	
		SP	27	36.9 ± 2.1 <b>h</b>	44.1 ± 1.6	
		Both	57	35.1 ± 1.5	41.2 ± 1.3	
ACP	AA	Male	RR	17		35.9 ± 2.6
		Female	RR	92		36.1 ± 1.0
		Both	RR	109		36.1 ± 0.9
UCSF	White	Male	RR	209	32.9 ± 0.6 (208)	
		Female	RR	445	32.6 ± 0.4 (437)	
		Both	RR	654	32.7 ± 0.4 (645)	

\*, Demographic data was available for 44 of the 45 male White patients.

**a**, P<0.05 versus corresponding VA White patients;

**b**, P<0.05 versus corresponding VA AA SPMS patients;

**c**, P<0.05 versus all VA White SPMS patients;

**d**, P<0.05 versus corresponding VA White SPMS patients;

**e**, P<0.05 versus corresponding White male SPMS patients;

**f**, P<0.05 versus corresponding ACP patients;

**g**, P<0.05 versus White female patients;

**h**, P<0.05 versus corresponding White patients.

Data is mean ± se. N is number in all groups unless otherwise indicated

ACP: Accelerated Cure Project; Dx: age at diagnosis; Sx: age at first sx

ACT, Accelerated Cure Project; DX, age at diagnosis; OX, age at onset; multiple sclerosis severity score; RR, relapsing remitting; SP, secondary

Years Dx-Sx	Duration from Diagnosis	Duration from Onset	EDSS	MSSS
2.5 ± 2.0	7.1 ± 1.6	9.5 ± 2.2	3.3 ± 0.5 <b>b</b>	4.3 ± 0.8 <b>b</b>
3.7 ± 1.1	8.1 ± 1.9	11.9 ± 2.5	6.5 ± 0.6 <b>f</b>	8.0 ± 0.5
3.0 ± 1.4	7.4 ± 1.2	10.3 ± 1.7	4.4 ± 0.5	5.8 ± 0.7
4.5 ± 2.1	8.5 ± 1.8	13 ± 2.7	3.8 ± 0.7 <b>b</b>	4.3 ± 0.8
6.2 ± 2.1	9.4 ± 2.4	15.6 ± 2.4	6.1 ± 0.2 <b>f</b>	6.5 ± 0.4
5.2 ± 1.5	8.8 ± 1.4	14 ± 1.9	4.7 ± 0.5	5.1 ± 0.6
3.3 ± 1.5	7.6 ± 1.2	10.8 ± 1.7	3.5 ± 0.4 <b>b</b>	4.3 ± 0.6 <b>b</b>
4.8 ± 1.1	8.7 ± 1.4	13.4 ± 1.8	6.3 ± 0.3 <b>c, f</b>	7.4 ± 0.4 <b>c</b>
3.8 ± 1.0	7.9 ± 0.9	11.8 ± 1.3	4.5 ± 0.4	5.5 ± 0.5
5.3 ± 1.8	8.5 ± 1.4	13.8 ± 2.2	3.1 ± 0.3 <b>e</b>	3.9 ± 0.5 <b>e</b>
5.0 ± 1.0	8.3 ± 0.9	13.3 ± 1.3	5.5 ± 0.4 <b>h</b>	6.3 ± 0.5 <b>h</b>
5.2 ± 1.1	8.4 ± 0.8	13.6 ± 1.3	4.2 ± 0.3 <b>h</b>	5.0 ± 0.4 <b>h</b>
5.5 ± 2.5	6.3 ± 1.6	11.8 ± 2.2	3.3 ± 0.9	3.8 ± 1.4
13.7 ± 3.6	8.6 ± 1.8	22.3 ± 4.2 <b>g</b>	4.9 ± 0.8 <b>h</b>	4.5 ± 1.3 <b>h</b>
9.9 ± 2.5	7.5 ± 1.2	17.5 ± 2.8	4.2 ± 0.6 <b>h</b>	4.2 ± 0.9
5.3 ± 1.5	8.1 ± 1.1	13.4 ± 1.8	3.1 ± 0.3 <b>d</b>	3.9 ± 0.5 <b>d</b>
7.3 ± 1.4	8.3 ± 0.8	15.6 ± 1.6	5.3 ± 0.3 <b>h</b>	5.8 ± 0.5 <b>h</b>
6.2 ± 1.0	8.2 ± 0.7	14.5 ± 1.2	4.2 ± 0.3 <b>h</b>	4.8 ± 0.4 <b>h</b>
	4.7 ± 1.0		3.3 ± 0.8 (5)	
	6.4 ± 0.6		4.1 ± 0.4 (37)	
	6.2 ± 0.6		4.0 ± 0.4 (42)	
		13.0 ± 0.7 (208)	2.9 ± 0.1 (208)	3.6 ± 0.2 (208)
		12.2 ± 0.5 (437)	2.7 ± 0.1 (434)	3.4 ± 0.1 (435)
		12.5 ± 0.4 (645)	2.7 ± 0.1 (642)	3.5 ± 0.1 (643)

l in parentheses. Parametric independent Ttest

mptom onset; EDSS: expanded disability severity scale; MSSS

symptom onset, EDSS, expanded disability severity scale, MDSSE,  
and progressive.

